Charles Cantor, PhD, Chief Scientific Officer, SequenomBio and Contact Info
Listen (6:39) What led you to Sequenom?
Listen (3:08) What has been the biggest challenge in commercializing NIPT?
Listen (6:12) Sequenom view on patent controversy
Listen (6:33) How good is the quality of the tests?
Listen (2:48) Do you plan to submit tests to FDA?
Listen (5:25) Diagnosing cancer during pregnancy and the issue of incidental findings
Listen (2:44) Three improvements needed from sequencing tools
Listen (3:07) The possibilities of in-utero therapy
On October 17 of 2011, Sequenom announced a clinical study had been published in the journal of Genetics in Medicine on their new sequencing based prenatal test for Down Syndrome. On the same day, the company launched their MaterniT21test. The rapid clinical adoption of this test--and those from three competing companies -- is without a doubt the biggest success story for the use of DNA sequencing in the clinic. According to the Wall Street Journal, in 2012, Sequenom alone sold 61.000 tests.
Today Fortune ran a piece on non-invasive prenatal testing (NIPT) predicting "the adoption of NIPT across the board as a standard test for all pregnant mothers, something as routine as ultrasound."
What has been the biggest challenge in commercializing a test using DNA sequencing? Does Sequenom have plans to submit the test to the FDA for approval? Dr. Cantor is not shy about answering tough questions. In today's show he walks us through the challenges the company faces, including emerging ethical quandaries such as the question of reporting incidental findings and the new possibilities for in-utero therapy.
Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.and by: Roche Molecular Systems: A proud sponsor of today's podcast.